Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Noxafil NDA Gets Priority Review | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Noxafil NDA Gets Priority Review

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough’s NDA for Noxafil Oral Suspension (for use in preventing serious invasive fungal infections (IFIs) in high-risk patients) has been granted a six-month priority review by the FDA. Priority review designation is granted to drugs that, if approved, would be a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease.

The company is seeking U.S. marketing approval of Noxafil for prophylaxis of serious invasive fungal infections, including both molds and yeasts, in patients who are at high risk of developing these infections; such as hematopoietic stem cell transplant (HSCT) recipients or those with prolonged neutropenia. The NDA also seeks marketing approval of Noxafil for the treatment of oropharyngeal candidiasis (OPC), including refractory infections. This indication will receive a 10-month review by FDA.

The company has filed a similar new drug application for Noxafil with the European Medicines Agency (EMEA). The product is currently approved in the EU for the treatment of certain invasive fungal infections (IFIs) in adult patients with disease that is refractory to or in patients who are intolerant of certain commonly used antifungal agents.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters